Dengue in travelers: A review

Journal of Travel Medicine

Volumn 11, Issue 3, 2004, Pages 161-170

  Wichmann, Ole ^a,b   Jelinek, Tomas ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b Institute of Tropical Medicine   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AEDES AEGYPTI; AVIATION; CLINICAL FEATURE; DENGUE; DENGUE VIRUS; EPIDEMIC; HUMAN; INFECTION CONTROL; INFECTION RISK; NONHUMAN; PALLIATIVE THERAPY; PATHOGENESIS; POLYMERASE CHAIN REACTION; PREVALENCE; REVIEW; RISK FACTOR; SYMPTOM; TRAVEL; VIRUS CARRIER; VIRUS CELL INTERACTION; VIRUS STRAIN;

EID: 3142510624     PISSN: 11951982     EISSN: None     Source Type: Journal    
DOI: 10.2310/7060.2004.18503     Document Type: Review

References (105)

1. Halstead S. The XXth century dengue pandemic: need for surveillance and research. World Health Statistics Q WHO Rep 1992; 45:292-298.
2. Kay B. Dengue vector surveillance and control. Curr Opin Infect Dis 1999; 12:425-432.
3. Rigau-Perez J, Clark G, Gubler D, et al. Dengue and dengue haemorrhagic fever. Lancet 1998; 352:971-977.
4. World Tourism Organization. World Tourism in 2002: better than expected. Released Madrid, 27 January 2003. Available at: http://www.worldtourism.org/ newsroom/ releases/2003/jan/numbers2002.htm (accessed 29 July 2003).
5. Stephan C, Allwinn R, Brodt HR. Travel-aquired dengue infection: clinical spectrum and diagnostic aspects. Infection 2002; 30:225-228.
6. O'Brien D, Tobin S, Brown GV, Torresi J. Fever in returned travellers: review of hospital admissions for a 3-year period. Clin Infect Dis 2001; 33:603-609.
7. Messer WB, Gubler DJ, Harris E, et al. Emergence and global spread of a dengue serotype 3, subtype III virus. Emerg Infect Dis 2003; 9:800-809.
8. Hanna JN, Ritchie SA, Phillips DA. An epidemic of dengue 3 in far north Queensland, 1997-1999. Med J Aust 2001; 174:178-182.
9. Das P. Infectious disease surveillance update. Lancet Infect Dis 2003; 3:267.
10. Kliks SC, Nimmanitya S, Nisalak A, Burke DS. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 1988; 38:411-419.
11. McBride WJ, Bielefeldt-Ohmann H. Dengue viral infections; pathogenesis and epidemiology. Microbes Infect 2000; 2:1041-1050.
12. Harrington LC, Edman JD, Scott TW. Why do female Aedes aegypti (Diptera: Culicidae) feed preferentially and frequently on human blood? J Med Entomol 2001; 38:411-422.
13. Platt KB, Linthicum KJ, Myint KSA, et al. Impact of dengue virus infection on feeding behaviour of Aedes aegypti. Am J Trop Med Hyg 1997; 57:119-125.
14. Rocco IM, Kavakama BB, Santos CL. First isolation of dengue 3 in Brazil from an imported case. Rev Inst Med Trop Sao Paulo 2001; 43:55-57.
15. Singh UB, Seth P. Use of nucleotide sequencing of the genomic cDNA fragments of the capsid/premembrane junction region for molecular epidemiology of dengue type 2 viruses. Southeast Asian J Trop Med Public Health 2001; 32:326-335.
16. Lifsori A. Mosquitos, models, and dengue. Lancet 1996; 347:1201-1202.
17. Gubler DJ. Epidemic dengue/dengue hemorrhagic fever: a global public health problem in the 21 st century. Dengue Bull 1997; 21:1-13.
18. World Health Organization. Dengue haemorrhagic fever. Diagnosis, treatment, prevention and control, 2nd edn. Geneva: WHO, 1997.
19. Gibbons RV, Vaughn DW. Dengue: an escalating problem. BMJ 2002; 324:1563-1566.
20. Gubler DJ. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 1998; 11:480-496.
21. Harris E, Videa E, Pérez L, et al. Clinical, epidemiologic, and virologic features of dengue in the 1998 epidemic in Nicaragua. Am J Trop Med Hyg 2000; 63:5-11.
22. Pinheiro F, Nelson M. Re-emergence of dengue and emergence of dengue haemorrhagic fever in the Americas. Dengue Bull 1997; 21:16-23.
23. Monath TP. Dengue: the risk to developed and developing countries. Proc Natl Acad Sci USA 1994; 91:2395-2400.
24. Jelinek T. Dengue fever in international travellers. Clin Infect Dis 2000; 31:144-147.
25. Romi R. Aedes albopictus in Italy: an underestimated health problem. Ann Ist Super Sanita 2001; 37:241-247.
26. Schaffner F, Karch S. First report of Aedes albopictus (Skuse, 1984) in metropolitan France. C R Acad Sci III 2000; 323:373-375.
27. Strickman D, Kittayapong P. Dengue and its vectors in Thailand: introduction to the study and seasonal distribution of Aedes larvae. Am J Trop Med Hyg 2002; 67:247-259.
28. Janisch T, Preiser W, Berger A, et al. Emerging viral pathogens in long-term expatriates (II): Dengue virus. Trop Med Int Health 1997; 2:934-940.
29. Eisenhut M, Schwarz TF, Hegenscheid B. Seroprevalence of dengue, chikungunya and Sindbis virus infections in German aid workers. Infection 1999; 27:82-85.
30. Potasman I, Srugo I, Schwartz E. Dengue seroconversion among Israeli travellers to tropical countries. Emerg Infect Dis 1999; 5:824-827.
31. Cobelens FGJ, Groen J, Osterhaus ADME, et al. Incidence and risk factors of probable dengue virus infection among Dutch travellers to Asia. Trop Med Int Health 2002; 7:331-338.
32. Lyerla R, Rigau-Perez JG, Vorndam AV, et al. A dengue outbreak among camp participants in a Caribbean island, 1995. J Travel Med 2000; 7:59-63.
33. Burke DS, Nisalak A, Johnson DE, Scott RM. A prospective study of dengue infection in Bangkok. Am J Trop Med Hyg 1988; 38:172-180.
34. Guzman MG, Kouri GP, Bravo J, et al. Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study. Am J Trop Med Hyg 1990; 42:179-184.
35. Wittesjö B, Eitrem R, Niklasson B. Dengue fever among Swedish tourists. Scand J Infect Dis 1993; 25:699-704.
36. Schwartz E, Sidi Y. Dengue fever among travelers. Am J Med 1996; 101:516-520.
37. Jelinek T, Mühlberger N, Harms G, et al. Epidemiology and clinical features of imported dengue fever in Europe: Sentinel surveillance data from TropNetEurop. Clin Infect Dis 2002; 35:1047-1052.
38. Lindbäck H, Lindbäck J, Tegnell A, et al. Dengue fever in travelers to the tropics, 1998 and 1999. Emerg Infect Dis 2003; 9:438-442.
39. Lawn SD, Tilley R, Lloyd G, et al. Dengue hemorrhagic fever with fulminant hepatic failure in an immigrant returning to Bangladesh. Clin Infect Dis 2003; 37:e1-e4.
40. Morens DM, Sather GE, Gubler DJ, et al. Dengue shock syndrome in an American traveller with primary dengue 3 infection. Am J Trop Med Hyg 1987; 36:424-426.
41. Wichmann O, Mühlberger N, Jelinek T. Dengue-the underestimated risk in travellers. Dengue Bull 2003; 27:126-137.
42. Lange WR, Beall B, Denny SC. Dengue fever: a resurgent risk for the international traveler. Am Fam Physician 1992; 45:1161-1168.
43. Melissant CF, Kauffmann RH. Infection with dengue virus. Neth J Med 1992; 41:272-274.
44. Chippaux A, Poveda JD. Imported dengue in France (1989-1993). Conditions to be met for assuring an accurate etiological diagnosis. Bull Soc Pathol Exot 1993; 86:402-405.
45. Hasler C, Schnorf H, Enderlin N, Gyr K. Imported dengue fever following a stay in the tropics. Schweiz Med Wochenschr 1993; 123:120-124.
46. Pick N, Potasman I. Dengue fever. Harefuah 1995; 129:30-32.
47. Lopez Velez R, Perez Casas C, Vorndam AV, Rigau J. Dengue in Spanish travelers returning from the tropics. Eur J Clin Microbiol Infect Dis 1996; 15:823-826.
48. Settah SG, Vernazza PL, Morant R, Schultze D. Imported dengue fever in Switzerland-serological evidence for a hitherto unexpectedly high prevalence. Schweiz Med Wochenschr 1995; 125:1673-1678.
49. Jelinek T, Dobler G, Hölscher M, et al. Prevalence of infection with dengue virus among international travelers. Arch Intern Med 1997; 157:2367-2370.
50. ProMED-mailing system: Dengue/DHF update 2003 (28), part [3]. Archive Number 20030714.1736, published 14.07.2003.
51. Clark GG, Rigau-Pérez JG, Vorndam V, Hayes JM. Imported dengue - United States, 1999 and 2000. MMWR 2002; 51:281-283.
52. Nimmannitya S. Clinical manifestations of dengue/dengue haemorrhagic fever. In: World Health Organization, Regional Office for South-East Asia. Monograph on dengue/ dengue haemorrhagic fever. Regional Publication No. 22. New Delhi: WHO, 1993:48-54.
53. Hayes EB, Gubler DJ. Dengue and dengue hemorrhagic fever. Pediatr Infect Dis J 1992; 11:311-317.
54. Kalayanarooj S, Vaughn DW, Nimmannitya S, et al. Early clinical and laboratory indicators of acute dengue illness. J Infect Dis 1997; 176:313-321.
55. Halstead SB. Antibody, macrophages, dengue virus infection, shock, and hemorrhage: a pathogenetic cascade. Rev Infect Dis 1989; 11:S830-S839.
56. World Health Organization. Guidelines for treatment of dengue fever/dengue haemorrhagic fever in small hospitals. New Delhi: WHO, 1999.
57. World Health Organization. Prevention and control of dengue and dengue haemorrhagic fever, comprehensive guidelines. New Delhi: WHO, 1999:11-19.
58. Wichmann O, Jelinek T. TropNetEurop: Surveillance of dengue in Europe. Euro Surveill Weekly 2003; 7(32).
59. Nimmannitya S, Thisyakorn U, Hemsrichart V. Dengue hemorrhagic fever with unusual manifestations. Southeast Asian J Trop Med Public Health 1987; 18:398-406.
60. Sirivichayakul C, Sabcharoen A, Chanthavanich P, et al. Dengue infection with unusual manifestation: a case report. J Med Assoc Thai 2000; 83:325-329.
61. Pancharoen C, Kulwichit W, Tantawichien T, et al. Dengue infection: a global concern. J Med Assoc Thai 2002; 85(Suppl 1):25-33.
62. Solomon T, Dung NM, Vaughn DW, et al. Neurological manifestations of dengue infection. Lancet 2000; 355:1053-1059.
63. Cam BV, Fonsmark L, Hue NB, et al. Prospective case-control study of encephalopathy in children with dengue hemorrhagic fever. Am J Trop Med Hyg 2001; 65:848-851.
64. Haritoglou C, Dotse SD, Rudolph G, et al. A tourist with dengue fever and visual loss. Lancet 2002; 360:1070.
65. Bethell DB, Gamble J, Loc PP, et al. Noninvasive measurement of microvascular leakage in patients with dengue hemorrhagic fever. Clin Infect Dis 2001; 32:243-253.
66. Akirutnan P, Malasit P, Seliger B, et al. Dengue virus infection of human endothelial cells leads to chemokine production, complement activation, and apoptosis. J Immunol 1998; 161:6338-6346.
67. Halstead SB, Pathogenesis of dengue: challenges to molecular biology. Science 1988; 239:476-481.
68. Green S, Vaughn DW, Kalajanarooj S, et al. Early immune activation in acute dengue illness is related to development of plasma leakage and disease severity. J Infect Dis 1999; 179:755-762.
69. Kliks SC, Nisalak A, Brandt WE, et al. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg 1989; 40:444-451.
70. Sangkawibha N, Rojanasuphot S, Ahandrik S, et al. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. Am J Epidemiol 1984; 120:653-669.
71. Thein S, Aung MM, Shwe TN, et al. Risk factors in dengue shock syndrome. Am J Trop Med Hyg 1997; 56:566-572.
72. Vaughn DW, Green S, Kalayanarooj S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000; 181:2-9.
73. Library DH, Endy TP, Houng HS, et al. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis 2002; 185:1213-1221.
74. Mongkolsapaya J, Dejnirattisai W, Xu X, et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med 2003; 9:921-927.
75. Barnes WJS, Rosen L. Fatal hemorrhagic disease and shock associated with primary dengue infection on a Pacific island. Am J Trop Med Hyg 1974; 23:495-506.
76. Leitmeter KC, Vaughn DW, Watts DM, et al. Dengue virus structural differences that correlate with pathogenesis. J Virol 1999; 73:4738-4747.
77. Watts DM, Porter KR, Putvatana P, et al. Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic fever. Lancet 1999; 354:1431-1434.
78. White NJ. Variation in virulence of dengue virus. Lancet 1999; 23:1401-1402.
79. Halstead SB, Streit TG, Lafontant JG, et al. Haiti: absence of dengue hemorrhagic fever despite hyperendemic dengue virus transmission. Am J Trop Med Hyg 2001; 65:180-183.
80. Loke H, Bethell DB, Phuong CXT, et al. Strong HLA class I-restricted T cell responses in dengue hemorrhagic fever: a double-edged sword? J Infect Dis 2001; 184:1369-1373.
81. Zivna I, Green S, Vaughn DW, et al. T cell responses to an HLA-B*07-restricted epitope on the dengue NS3 protein correlate with disease severity. J Immunol 2002; 168:5959-5965.
82. Halstead SB. Dengue. Curr Opin Infect Dis 2002; 15:471-476.
83. Innis BL, Nisalak A, Nimmannitya S, et al. An enzyme-linked immunosorbent assay to characterize dengue infections where dengue and Japanese encephalitis co-circulate. Am J Trop Med Hyg 1989; 40:418-427.
84. Lam SK, Devine PL. Evaluation of capture ELISA and rapid immunochromatographic test for the determination of IgM and IgG antibodies produced during dengue infection. Clin Diagn Virol 1998; 10:75-81.
85. Schwartz E, Mileguir F, Grossman Z, Mendelson E. Evaluation of ELISA-based sero-diagnosis of dengue fever in travelers. J Clin Virol 2000; 19:169-173.
86. Vaughn DW, Green S, Kalajanarooj S, et al. Dengue in the early febrile phase: viremia and antibody responses. J Infect Dis 1997; 176:322-330.
87. Gascon J, Giner V, Vidal J, et al. Dengue: a re-emerging disease. A clinical and epidemiological study in 57 Spanish travelers. Med Clin (Barc) 1998; 111:583-586.
88. LaRussa VF, Innis BL. Mechanisms of dengue virus-induced bone marrow suppression. Baillieres Clin Haematol 1995; 8:249-270.
89. Lin CF, Lei HY, Liu CC, et al. Generation of IgM anti-platelet autoantibody in dengue patients. J Med Virol 2001; 63:143-149.
90. Phuong CXT, Nhan NT, Wills B, et al. Evaluation of the World Health Organization standard tourniquet test and a modified tourniquet test in the diagnosis of dengue infection in Viet Nam. Trop Med Int Health 2002; 7:125-132.
91. Nimmannitya S. Clinical spectrum and management of dengue haemorrhagic fever. Southeast Asian J Trop Med Public Health 1987; 18:392-397.
92. Nhan NT, Phuong CXT, Kneen R, et al. Acute management of dengue shock syndrome: a randomized double-blind comparison of 4 intravenous fluid regimens in the first hour. Clin Infect Dis 2001; 32:204-213.
93. Chambers T, Tsai T, Pervokov Y, Monath T. Vaccine development against dengue and Japanese encephalitis: report of a World Health Organization meeting, Vaccine 1997; 15:1494-1502.
94. Morens DM. Antibody-dependent enhancement of infection and the pathogenesis of viral disease. Clin Infect Dis 1994; 19:500-512.
95. Sabchareon A, Lang J, Chanthavanich P, et al. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg 2002; 66:264-272.
96. Bhamarapravati N, Sutee Y. Live attenuated tetravalent dengue vaccine. Vaccine 2000; 18:44-47.
97. Kanesa-thasan N, Sun W, Kim-Ahn G, et al. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 2001; 19:3179-3188.
98. Kinney R, Butrapet S, Chang G, et al. Construction of infectious cDNA for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53. Virology 1997; 230:300-308.
99. Schoepke A, Steffen R, Gratz N. Effectiveness of personal protection measures against mosquito bites for malaria prophylaxis in travellers. J Travel Med 1998; 5:188-192.
100. Fradin MS, Day JF. Comparative efficacy of insect repellents against mosquito bites. N Engl J Med 2002; 347:13-18.
101. Nentwig G. Use of repellents as prophylactic agents. Parasitol Res 2003; 90:S40-S48.
102. Gubler D, Kuno G, Sather G, et al. Mosquito cell cultures and specific monoclonal antibodies in surveillance for dengue viruses. Am J Trop Med Hyg 1984; 33:156-165.
103. Yabe S, Nakayama M, Yamada K, et al. Laboratory virological diagnosis of imported dengue cases. Kansenshogaku Zasshi 1996; 70:1160-1169.
104. Halstead S, Udomsakdi S, Singharaj P, Nissalakk A. Dengue and Chinkungunya virus infection in man in Thailand, 1962-64 III: clinical, epidemiologic, and virologic observations on disease in non-indigenous white persons. Am J Trop Med Hyg 1969; 18:984-996.
105. Gratz NG, Knudsen AB. The rise and spread of dengue, dengue haemorrhagic fever and its vectors-a historical review (CTD/FIL (DEN) 96.7). Geneva: World Health Organisation, 1996.